Vimarsana
Biggest News Aggregation in the World

Page 4 - Motor Function News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Motor Function. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Motor Function Today - Breaking & Trending Today

Gene therapy may restore mobility after spinal cord injury, animal study finds - Vimarsana News

Gene therapy may restore mobility after spinal cord injury, animal study finds

Gene therapy has restored mobility in mice with completely severed spinal cords, researchers report.

Source: yahoo.com
FOXNEWS Fox News Tonight June 4, 2024 00:02:15 - Vimarsana News

FOXNEWS Fox News Tonight June 4, 2024 00:02:15

Late edition of the television news program by the Fox News editorial staff.

Related Topics:
Motor Function
FOXNEWS Fox News Tonight June 4, 2024 05:02:30 - Vimarsana News

FOXNEWS Fox News Tonight June 4, 2024 05:02:30

Late edition of the television news program by the Fox News editorial staff.

Related Topics:
Motor FunctionOf Es
New Four-Year Data for Genentech's Evrysdi Reinforce Long-Term Efficacy and Safety Profile in Some of the Most Severely Affected People With Types 2 and 3 Spinal Muscular Atrophy (SMA) Seite 1 - Vimarsana News

New Four-Year Data for Genentech's Evrysdi Reinforce Long-Term Efficacy and Safety Profile in Some of the Most Severely Affected People With Types 2 and 3 Spinal Muscular Atrophy (SMA) Seite 1

20.03.2023 - Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced new long-term data for Evrysdi (risdiplam) in a broad range of people aged 2-25 years with spinal muscular atrophy (SMA) from the pivotal SUNFISH study. Data ... Seite 1

FDA Asks Gene Therapy Biotech to Run Clinical Trial That Might Be Impossible - Vimarsana News

FDA Asks Gene Therapy Biotech to Run Clinical Trial That Might Be Impossible

Taysha Gene Therapies has encouraging data from an open-label, Phase 1/2 study in the rare disease giant axonal neuropathy. It might not be enough. The FDA recommended the biotech conduct a randomized and placebo-controlled study—a challenge in any ultra-rare disease.